Emily Burkett, NP
Nurse Practitioner · Evansville, INNPI 1912315466
Payments from drug & device makers
Across 267 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$669
- Sumitomo Pharma America, Inc.$654
- C. R. Bard, Inc. & Subsidiaries$535
- Astellas Pharma US Inc$454
- 180 Medical, Inc.$406
- AbbVie$231
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,18495%
- Education$2775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 32 | $669 |
| Sumitomo Pharma America, Inc. | 37 | $654 |
| C. R. Bard, Inc. & Subsidiaries | 20 | $535 |
| Astellas Pharma US Inc | 27 | $454 |
| 180 Medical, Inc. | 17 | $406 |
| AbbVie(2 entities) | 15 | $231 |
| Rochester Medical Corporation | 5 | $216 |
| Antares Pharma, Inc. | 5 | $185 |
| Medtronic | 10 | $180 |
| Myriad Genetic Laboratories, Inc. | 9 | $163 |
| Urovant Sciences Inc | 14 | $155 |
| GSK | 6 | $121 |
| Pfizer | 6 | $120 |
| Merck | 6 | $117 |
| Tolmar, Inc. | 5 | $104 |
| Endo Pharmaceuticals Inc. | 5 | $95 |
| Tolmar Pharmaceuticals, Inc. | 5 | $91 |
| Seagen Inc. | 1 | $85 |
| Myovant Sciences Inc. | 4 | $84 |
| Lilly USA, LLC | 1 | $74 |
| Olympus America Inc. | 3 | $72 |
| Novartis | 4 | $70 |
| Sun Pharmaceutical Industries Inc. | 3 | $68 |
| Blue Earth Diagnostics | 3 | $67 |
| Accord Healthcare, Inc. | 3 | $57 |
| Teleflex LLC | 2 | $50 |
| Urogen Pharma, Inc. | 3 | $46 |
| Koelis Inc. | 2 | $38 |
| Boston Scientific | 1 | $35 |
| Axonics, Inc. | 2 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $22 |
| Hollister Incorporated | 1 | $21 |
| Immunitybio, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Photocure Inc | 1 | $17 |
| Bayer | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Intuitive Surgical | 1 | $13 |
| Coloplast | 1 | $12 |
| Sagent Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,461 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 334 | $273,846 |
| MyrbetriqMirabegron | 199 | $146,452 |
| Trospium Chloride | 184 | $11,331 |
| Potassium Citrate ErPotassium Citrate | 60 | $6,550 |
| Testosterone | 12 | $4,405 |
| Tamsulosin Hcl | 313 | $3,461 |
| Estradiol | 30 | $1,752 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $1,699 |
| Methenamine Hippurate | 32 | $1,592 |
| Solifenacin Succinate | 33 | $1,426 |
| Trimethoprim | 19 | $994 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $847 |
| Finasteride | 66 | $693 |
| Tolterodine Tartrate | 13 | $660 |
| Testosterone Cypionate | 20 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $654 | $273,846334 claims |
| Astellas Pharma US IncMyrbetriq | $454 | $146,452199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Evansville
- Stacey RickettsEvansville$18K
- Helen EvansEvansville$9K
- Kirk AshburnEvansville$9K
- Zhuang SantacanaEvansville$9K
- Brittney PhippsEvansville$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.